Two cases of suspected myocarditis following COVID-19 mRNA vaccination in men aged 27 and 37 recovered with symptomatic relief within a few days.
Case Report (n=2)
What are the clinical characteristics and outcomes of suspected myocarditis following COVID-19 mRNA vaccination in young men?
COVID-19 mRNA vaccine-related myocarditis can occur in young men but appears to resolve quickly with symptomatic treatment, supporting the continued overall benefit of vaccination.
COVID-19 vaccine-related myocarditis has been reported worldwide. We herein report two Japanese cases with suspected vaccine-related myocarditis. A 27-year-old man was admitted with chest pain 4 days after the second vaccination. An electrocardiogram (ECG) did not reveal any significant abnormalities. The second patient, a 37-year-old man, was admitted with chest pain 9 days after the first vaccination. His ECG exhibited ST-elevation in multiple leads. In both cases, cardiac magnetic resonance imaging findings were consistent with myocarditis. They recovered with symptomatic relief within a few days. These cases suggest that the benefit of COVID-19 vaccination exceeds the risk of vaccine-related myocarditis.
Murakami et al. (Fri,) conducted a case report in COVID-19 vaccine-related myocarditis (n=2). COVID-19 mRNA vaccination was evaluated. Two cases of suspected myocarditis following COVID-19 mRNA vaccination in men aged 27 and 37 recovered with symptomatic relief within a few days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: